-
Publication Venue For
-
Efficacy and safety of ketamine in the management of anxiety and anxiety spectrum disorders: a review of the literature..
25:331-342.
2020
-
142 Withdrawal Symptom Assessment in an Esketamine Safety Study in Patients with Treatment-resistant Depression..
25:290.
2020
-
Guidance for switching from off-label antipsychotics to pimavanserin for Parkinson's disease psychosis: an expert consensus..
24:574-575.
2019
-
Guidance for switching from off-label antipsychotics to pimavanserin for Parkinson's disease psychosis: an expert consensus..
23:402-413.
2018
-
Efficacy and safety of selegiline transdermal system (STS) for the atypical subtype of major depressive disorder: pooled analysis of 5 short-term, placebo-controlled trials..
19:324-329.
2014
-
Effectiveness of lurasidone in schizophrenia or schizoaffective patients switched from other antipsychotics: a 6-month, open-label, extension study.
1-10.
2013
-
Attitudes toward borderline personality disorder: a survey of 706 mental health clinicians..
16:67-74.
2011
-
White matter hyperintensities and their association with suicidality in major affective disorders: a meta-analysis of magnetic resonance imaging studies..
15:375-381.
2010
-
Evaluation of the Effects of Severe Depression on Global Cognitive Function and Memory..
15:304-313.
2010
-
Separating hope from hype: some ethical implications of the development of deep brain stimulation in psychiatric research and treatment..
15:285-287.
2010
-
Understanding therapeutic equivalence in epilepsy..
15:112-123.
2010
-
The clinical future of repetitive transcranial magnetic stimulation and depression: Separating hope from hype.
15:554-557.
2010
-
FDA considers classification of ECT..
14:668-670.
2009
-
The role of non-pharmacologic approaches in the management of fibromyalgia..
14:10-12.
2009
-
The treatment of primary insomnia..
14:6-10.
2009
-
Decision-making and prepotent response inhibition functions in excessive internet users..
14:75-81.
2009
-
Neuropsychological characterization of dementia patients..
13:10-13.
2008
-
Impulse-control disorders in Parkinson's disease..
13:690-698.
2008
-
Inflammation, Glutamate, and Glia in Depression: A Literature Review.
13:501-510.
2008
-
Comorbid HIV encephalopathy and cocaine use as a risk factor for new-onset seizure disorders..
13:230-234.
2008
-
Impulse-control disorders in Parkinson's disease.
13:690-698.
2008
-
Neuropsychological characterization of dementia patients.
13:10-13.
2008
-
Long-term issues in the treatment of sleep disorders..
12:1-14.
2007
-
Coenzyme Q10: a review of its promise as a neuroprotectant..
12:62-68.
2007
-
The Morbidity of Insomnia.
12:6-8.
2007
-
Resilience: Determinants, measurement, and treatment responsiveness.
11:5-12.
2006
-
The use of antiepileptic drugs in bipolar disorders: a review based on evidence from controlled trials..
11:788-799.
2006
-
Mixed amphetamine salts extended-release in the treatment of adult ADHD: a randomized, controlled trial..
11:625-639.
2006
-
Introduction: An overview of the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) study.
11:4-8.
2006
-
Transdermal selegiline: the new generation of monoamine oxidase inhibitors..
11:363-375.
2006
-
Refractory calculation-induced idiopathic generalized epilepsy: A case report and review of the literature.
11:50-51.
2006
-
Long-term cardiovascular effects of mixed amphetamine salts extended release in adults with ADHD..
10:35-43.
2005
-
Statins and cognition: what can we learn from existing randomized trials?.
10:867-874.
2005
-
Safety considerations in pharmacotherapy of bipolar disorder.
9:16-26.
2004
-
Safety considerations in pharmacotherapy of bipolar disorder..
9:16-26.
2004
-
Cognitive deficits following coronary artery bypass grafting: prevalence, prognosis, and therapeutic strategies..
9:763-772.
2004
-
Generalized anxiety disorder: acute and chronic treatment..
9:716-723.
2004
-
New Challenges for Anxiety Disorders: Where Treatment, Resilience, and Economic Priority Converge.
9:1-9.
2004
-
Managing the risks of repetitive transcranial stimulation..
8:489.
2003
-
New developments in electroconvulsive therapy and magnetic seizure therapy..
8:529-536.
2003
-
How well does cognitive-behavioral therapy treat symptoms of complex PTSD? An examination of child sexual abuse survivors within a clinical trial..
8:340-355.
2003
-
Response of the norepinephrine system to antidepressant drugs.
6:679-684.
2001
-
Adverse-effect profile of kava..
6:848-853.
2001
-
Evaluating medicinal herbs..
6:826.
2001
-
The self-assessment of resilience and anxiety: psychometric properties..
6:854-857.
2001
-
The use of valerian in neuropsychiatry..
6:841-847.
2001
-
Protein kinase a in major depression: the link between hypothalamic-pituitary-adrenal axis hyperactivity and neurogenesis..
6:565-572.
2001
-
Combination pharmacotherapy in alcoholism: a novel treatment approach..
5:70-76.
2000
-
Apathy in neuropsychiatrie disorders.
4:31-50.
1999
-
A Consensus Meeting on Effective Research Practice in PTSD.
3:6-10.
1998
-
Making headway - New treatments in Parkinson's disease.
3:22.
1998
-
Recognizing and treating nonmotor disorders associated with Parkinson's disease.
3:41-45.
1998
-
The Role of Serotonin in Posttraumatic Stress Disorder: Neurobiology and Pharmacotherapy.
3:42-51.
1998
-
Cognitive impairment in schizophrenia and implications of atypical neuroleptic treatment.
2:41-55.
1997
-
Cognitive impairment in schizophrenia and implications of atypical neuroleptic treatment.
2:41-55.
1997
-
Refractory calculation-induced idiopathic generalized epilepsy. A case report and review of the literature
2006